Quantifying cognitive resilience in Alzheimer’s Disease: The Alzheimer’s Disease Cognitive Resilience Score

Abstract

Even though there is a clear link between Alzheimer’s Disease (AD) related neuropathology and cognitive decline, numerous studies have observed that healthy cognition can exist in the presence of extensive AD pathology, a phenomenon sometimes called Cognitive Resilience (CR). To better understand and study CR, we develop the Alzheimer’s Disease Cognitive Resilience Score (AD-CR Score), which we define as the difference between the observed and expected cognition given the observed level of AD pathology. Unlike other definitions of CR, our AD-CR Score is a fully non-parametric, stand-alone, individual-level quantification of CR that is derived independently of other factors or proxy variables. Using data from two ongoing, longitudinal cohort studies of aging, the Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP), we validate our AD-CR Score by showing strong associations with known factors related to CR such as baseline and longitudinal cognition, non AD-related pathology, education, personality, APOE, parkinsonism, depression, and life activities. Even though the proposed AD-CR Score cannot be directly calculated during an individual’s lifetime because it uses postmortem pathology, we also develop a machine learning framework that achieves promising results in terms of predicting whether an individual will have an extremely high or low AD-CR Score using only measures available during the lifetime. Given this, our AD-CR Score can be used for further investigations into mechanisms of CR, and potentially for subject stratification prior to clinical trials of personalized therapies.

Physical activity, biomarkers of brain pathologies and dementia risk: Results from the Memento clinical cohort

“…21 Up to date, only a few studies have explored the contribution of physical activity to cognitive reserve while accounting for brain pathology. 22,[24][25][26]28,29,45 They yielded heterogeneous findings.…”

Integrated Proteomics Identifies Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer’s Disease

“…Recent reports indicate Black and Hispanic populations are disproportionately more likely to have AD compared to older white Americans (64), which highlights a potential limitation of the current study. In addition to population demographics, the use of multiple definitions of resilience and how researchers identify this group adds complexity to generalizable interpretation of findings (7, 8). The current study used the combination of pathological and cognitive metrics to differentiate asymptomatic from symptomatic cases by imposing cutoffs which would identify resilient cases with the greatest confidence, however, there may be more to learn from cases not captured by this strategy.…”

The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence

“…This is a staging tool crucial to determine whether an individual is diagnosed as MCI or AD, and is usually complemented by the Mini Mental State Examination (MMSE) score, which measures overall cognitive status. For instance, the study by Yao and colleagues (2020 [ 60 ]. described the use of a ML model (GB and SVM) that helped to generate a cognitive resilience score, which they defined as the difference between the observed and expected cognitive status displayed by an AD patient with a specific presumed level of AD pathology.…”